Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD3 | Q9H7B4 | 15/20 | 0.50 |
| ▸ | CDK1 | P06493 | 1/20 | 0.50 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.50 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.50 |
| ▸ | CDK2 | P24941 | 1/20 | 0.50 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.49 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19701368 | 1.00 | SMYD3 (0.50) | SMYD3CDK1CCNB1CCNA2CDK2 | |
| SCHEMBL26412830 | 0.85 | HSD11B1 (0.63) | PRKAA2HSD11B1 | |
| SCHEMBL19701366 | 0.84 | SMYD3 (0.51) | SMYD3HSD11B1 | |
| SCHEMBL21490144 | 0.84 | SMYD3 (0.51) | SMYD3HSD11B1 | |
| SCHEMBL23575973 | 0.84 | SMYD3 (0.65) | SMYD3 | |
| SCHEMBL19710214 | 0.84 | SMYD3 (0.65) | SMYD3 | |
| SCHEMBL12513462 | 0.83 | PRKAA2 (0.47) | SMYD3PRKAA2HSD11B1 | |
| SCHEMBL12437375 | 0.83 | PRKAA2 (0.47) | SMYD3PRKAA2HSD11B1 | |
| SCHEMBL31514789 | 0.83 | CNR2 (0.59) | PRKAA2HSD11B1 | |
| SCHEMBL21490050 | 0.80 | SMYD3 (0.50) | SMYD3HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210198252-A1 | SMYD INHIBITORS | EPIZYME INC (US) | 2021-07-01 | — | — | US | claimed |
| US-20190322660-A1 | SMYD INHIBITORS | Epizyme, Inc. | 2019-10-24 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210198252-A1 | SMYD INHIBITORS | SMYD3, SMYD2, SMURF2 | SMYD3 1/4885CDK1 4152/4885CCNB1 2497/4885 |
| US-20190322660-A1 | SMYD INHIBITORS | SMYD2, SMYD3, SMURF2 | SMYD3 2/4885CDK1 4033/4885CCNB1 2580/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.